Celltrion Healthcare Launches Herzuma In Brazil

• Brazilian stand, Herzuma Launching Symposium ... Targeting the largest market in Latin America worth KRW 270 billion
• Truxima obtained marketing approval in Brazil two months standing ... Direct sales started in the first half of next year

Celltrion Healthcare has launched Herzuma, a biosimilar for the treatment of breast and stomach cancer in Brazil, the largest pharmaceutical market in Latin America.

Celltrion Healthcare is a biopharmaceutical industry official, a leading key Opinion Leader (KOL) doctor, a large insurer, and a hospital medicinal agent at the SBOC^[1] Brazilian Clinical Oncology Congress held in Rio de Janeiro, Brazil, on the 24th. The company officially launched the Herzuma Symposium by inviting purchasers.

At the event, Celltrion Healthcare will explain Herzuma's global clinical data and sales status, while presenting the strengths of Herzuma that can lead to improved patient access and lower financial costs. High interest and response was received.

Brazil is regarded as a core country in Latin America, with a marketable market of about 270 billion won. Unlike in the past, Brazil is creating a positive market environment to expand the biosimilar market by changing the atmosphere for introducing biosimilars into the public insurance market. Celltrion Healthcare will focus on Herzuma through this launching symposium, and plan to collaborate with partners to continue marketing activities for the preoccupation of the Brazilian market centered on major hospitals specialized in anticancer.

Celltrion Healthcare's first anticancer product, Truxima (ingredient name: Rituximab), will receive marketing approval from a Brazilian licensing agency this month to further strengthen the synergy of its three major products. The Brazilian market for the three products in circulation is about W530bn, which is half of the market in Latin America. Celltrion Healthcare plans to sell Truxima directly in Brazil in the first half of next year, and is expanding its distribution network and recruiting local employees through its local subsidiary in Brazil.

Celltrion Group biosimilar market expansion in Brazil and Latin America is expected to accelerate. Celltrion Healthcare held Truxima in Chile and Truxima in Peru in August, ahead of the Herzuma launching symposium in Brazil in August. The company plans to launch a full-fledged attack on Central and South America starting in the second half of this year.

An official of Celltrion Healthcare said, “As the country's launch symposium attended by key stakeholders in the biopharmaceutical industry, we expect the expansion of the Latin American market of three products will be faster.” Starting with Brazil Truxima, we are preparing direct sales of Herzuma in Colombia, Mexico, Chile, and Peru.

^[1] SBOC: The Brazilian Society of Clinical Oncology